Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Immunex Novantrone

Executive Summary

Immunex Novantrone: Firm files supplemental NDA for use of mitoxantrone in the treatment of hormone-refractory prostate cancer, Immunex announces May 14. The company is seeking a priority review for the NDA, which includes two Phase III trials in 303 patients who previously had failed hormone treatment. In one study, serum PSA declined by 50% or more for 44% of the patients receiving Novantrone plus prednisone compared to 33% of the patients on prednisone alone. In the second study, PSA decreases of 50% or more were seen in 31% of the Novantrone patients compared to 17% of the steroid-only group. In addition, Novantrone treatment resulted in significant improvements in pain and overall quality of life. Novantrone is marketed in the U.S. as first-line therapy for acute myelogenous leukemia...

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts